Keyphrases
Gastroesophageal Reflux Disease
100%
South Africa
75%
Inhibitor Agent
75%
Proton Pump Inhibitors
75%
Pharmacotherapeutic Management
75%
Cytoprotective Agents
75%
Acid Suppressant
75%
Irritation
75%
Histamine-2 Receptor Antagonists (H2RA)
75%
Acid Production
75%
Causal Factors
75%
Motility
75%
Antacids
75%
Opioid Analgesics
75%
Treatment Options
66%
Fixed-dose Combinations of Antihypertensive Drugs
50%
Pharmacogenetics
50%
Pharmaceutics
50%
Sustainable Access
50%
Missing Components
50%
Pharmacist Perspectives
50%
Gastroesophageal Reflux
50%
Opioid Metabolism
50%
Antimicrobial Stewardship
50%
Two-country
50%
Dyslipidemia
50%
Antimicrobial
50%
Allergy
50%
Antihistamines
50%
Opioids
50%
Muscle Pain
50%
μ-opioid Receptor
50%
Allergic Diseases
50%
Fixed-dose Combination Therapy
33%
Hypertension
33%
Allergic Reaction
33%
Lipid Abnormalities
33%
Pediatric Population
33%
Pharmacist
29%
Antimicrobial Resistance
25%
Metabolism
25%
Cost-effectiveness
25%
Treatment Efficacy
25%
Appropriate Therapy
25%
Procurement Process
25%
Opioid Pharmacokinetics
25%
Patient Response
25%
Bioactivation
25%
Moderate to Severe
22%
Large Obstacle
16%
Pharmacology, Toxicology and Pharmaceutical Science
Gastroesophageal Reflux
100%
Antihypertensive Drug
50%
Combination Therapy
50%
Cytoprotective Agent
50%
Proton Pump Inhibitor
50%
Antiinfective Agent
50%
Histamine H2 Receptor Antagonist
50%
Antacid Agent
50%
Acid
50%
Pharmacogenetics
50%
Antihistaminic Agent
50%
Allergy
50%
Opiate
50%
Allergic Reaction
33%
Histamine H1 Receptor Antagonist
33%
Antihypertensive Agent
25%
Cardiovascular Risk
25%
Tolerability
25%
Pharmacotherapy
25%
Side Effect
25%
Antimicrobial Resistance
25%
Antibiotic Resistance
25%
Allergic Asthma
16%
Immunoglobulin E
16%
Atopic Dermatitis
16%
Allergic Rhinitis
16%
Bioactivation
12%
Narcotic Analgesic Agent
12%
Tramadol
6%
CYP2D6
6%
Pharmacogenomics
6%
CYP3A4
6%
Nociceptive Pain
6%
Pharmacodynamics
6%
Codeine
6%
Analgesic Agent
6%
Receptor
6%
Pharmacokinetics
6%
